XHKG
2666
Market cap1.16bUSD
Jul 09, Last price
4.53HKD
1D
-1.31%
1Q
-22.83%
Jan 2017
-29.33%
IPO
-34.44%
Name
Genertec Universal Medical Group Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genertec Universal Medical Group Company Limited, founded in 1984 and based in Beijing, China, provides extensive financing and advisory services across the People's Republic of China, alongside operating a significant healthcare business. The company's operations are segmented into two primary divisions. The Finance and Advisory segment delivers a range of services including direct finance leasing, sale-and-leaseback arrangements, factoring, operating leases, and various advisory offerings. Meanwhile, its Hospital Group segment focuses on providing medical care, managing hospitals and healthcare facilities, and conducting import, export, and general trading of medical-related goods. Beyond these core areas, Genertec Universal Medical also engages in medical technology development, hospital digitalization, construction, and management services, as well as property management and medical consulting. The company serves a diverse clientele, encompassing patients, hospitals, medical equipment suppliers, and other public sector organizations. In July 2018, the company adopted its current name, having previously operated as Universal Medical Financial & Technical Advisory Services Company Limited.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||